Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
33.5M
-
Shares change
-
-84K
-
Total reported value, excl. options
-
$164M
-
Value change
-
-$5.48M
-
Put/Call ratio
-
0.21
-
Number of buys
-
66
-
Number of sells
-
-82
-
Price
-
$4.91
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q1 2023
190 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.5M shares
of 54.8M outstanding shares and own 61.11% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.6M shares), VANGUARD GROUP INC (3.12M shares), Bain Capital Life Sciences Investors, LLC (2.2M shares), FARALLON CAPITAL MANAGEMENT LLC (2M shares), STATE STREET CORP (1.9M shares), DISCIPLINED GROWTH INVESTORS INC /MN (1.73M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (1.23M shares), Chescapmanager LLC (1.16M shares), DIMENSIONAL FUND ADVISORS LP (946K shares), and GEODE CAPITAL MANAGEMENT, LLC (892K shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.